The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation
蛋白酶体和溶酶体降解之间相互作用的 NRF2-p62 轴
基本信息
- 批准号:9311709
- 负责人:
- 金额:$ 36.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAnimalsAntioxidantsAttenuatedBindingCardiacCardiac MyocytesCardiomyopathiesCause of DeathClinical ManagementCongestive Heart FailureDiagnosisDiseaseExcisionFeedbackFunctional disorderGTF2H1 geneGene TargetingGeneticGenetic ModelsGoalsHealthcareHeartHeart DiseasesHeart failureImpairmentInjuryKnock-outLifeLinkLiteratureMeasuresMediatingMolecularMusMyocardialMyocardial dysfunctionMyocardiumOrganellesOutcomePathologyPathway interactionsPerformancePharmaceutical PreparationsPharmacologyPhasePilot ProjectsPlayProteasome InhibitionProteinsQuality ControlResearchResearch Project GrantsRoleStressSyndromeSystemTestingToxic effectTransgenic MiceTransgenic OrganismsUbiquitinUbiquitinated Protein DegradationUbiquitinationUp-Regulationcardiogenesisclinical translationconstrictionhuman morbidityhuman mortalityhypertensive heart diseasein vivoinnovationinsightmisfolded proteinmulticatalytic endopeptidase complexnovelnovel therapeutic interventionnuclear factor-erythroid 2pressurepreventprogramsprotein aggregateprotein degradationsham surgerytranscription factorvirtual
项目摘要
Heart failure is a leading cause of human mortality and morbidity without a cure. Protein degradation by the
ubiquitin-proteasome system (UPS) and the autophagic-lysosomal pathway (ALP) is pivotal to cardiac protein
quality control which acts to minimize the level and toxicity of misfolded proteins in cardiomyocytes. Protein
quality control inadequacy resulting from UPS and ALP dysfunctions is implicated in the development of heart
failure from a variety of heart diseases including pressure overload (PO) disorders. Proteasome inhibition
activates ALP while ALP impairment can compromise UPS performance, suggesting an intricate interplay
between UPS and ALP dysfunctions. However, such interplay in diseased hearts and its underlying
mechanisms remain to be defined. Therefore the long term goal of this research project is to delineate the
molecular basis of UPS-ALP crosstalk. Literature and our pilot studies suggest that NRF2 (nuclear factor-
erythroid 2-related factor 2) and its target gene p62/SQSTM1 may act as a molecular link in the impairment of
UPS performance by ALP insufficiency but this remains to be established in the heart. Hence, we propose to
determine the role of the Nrf2-p62 axis in regulating ALP-UPS cross-talk in pressure overloaded hearts. The
central hypothesis to be tested is that activation of the Nrf2-p62 axis plays a major mediating role in the
impairment of UPS performance by ALP insufficiency in pressure overloaded hearts. We will pursue 2
specific aims. Aim 1 will determine the role of Nrf2 in the induction of cardiac UPS impairment and maladaptive
remodeling by ALP impairment in PO hearts. Aim 2 will investigate the molecular mechanism by which Nrf2
exacerbates cardiac injury in ALP insufficient hearts, testing the hypothesis that induction of p62 by Nrf2
impairs UPS performance in ALP deficient hearts. This project will likely provide new mechanistic insight into
UPS-ALP interplay in the heart and establish a new concept that enhancing ALP while activating Nrf2 is a
better strategy than Nrf2 activation alone for treating heart disease.
心力衰竭是人类死亡和发病的主要原因,但无法治愈。蛋白质降解
泛素-蛋白酶体系统(UPS)和自噬-溶酶体途径(ALP)是心脏蛋白的关键
质量控制,其作用是使心肌细胞中错误折叠蛋白质的水平和毒性最小化。蛋白
UPS和ALP功能障碍导致的质量控制不足与心脏的发育有关
包括压力超负荷(PO)紊乱在内的各种心脏病导致的衰竭。蛋白酶体抑制
激活ALP,而ALP损伤可损害UPS性能,这表明一种复杂的相互作用
UPS和ALP功能障碍之间的联系然而,这种相互作用在患病的心脏和其潜在的
机制尚待确定。因此,本研究项目的长期目标是描绘
UPS-ALP串扰的分子基础。文献和我们的初步研究表明,NRF 2(核因子-
红细胞2相关因子2)及其靶基因p62/SQSTM 1可能在红细胞2相关因子2受损中起分子联系作用。
ALP功能不全的UPS性能,但这仍有待建立在心脏。因此,我们建议
确定Nrf 2-p62轴在压力超负荷心脏中调节ALP-UPS串扰的作用。的
待检验的中心假设是Nrf 2-p62轴的激活在细胞凋亡中起主要的介导作用。
压力超负荷心脏中ALP不足对UPS性能的损害我们将继续追求2
具体目标。目的1将确定Nrf 2在诱导心脏UPS损伤和适应不良中的作用。
在PO心脏中通过ALP损伤进行重构。目的2将研究Nrf 2在细胞中的作用机制,
加剧了ALP不足心脏的心脏损伤,验证了Nrf 2诱导p62的假设,
损害ALP缺乏心脏的UPS性能。该项目可能会提供新的机械见解,
UPS-ALP在心脏中相互作用,并建立了一个新的概念,即在激活Nrf 2的同时增强ALP是一种新的治疗方法。
比单独激活Nrf 2更好的治疗心脏病的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taixing Cui其他文献
Taixing Cui的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taixing Cui', 18)}}的其他基金
Cyclin-dependent kinase (CDK)19-mediated vein graft intimal hyperplasia
细胞周期蛋白依赖性激酶(CDK)19介导的静脉移植内膜增生
- 批准号:
10664327 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Metabolic control of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的代谢控制
- 批准号:
10829610 - 财政年份:2021
- 资助金额:
$ 36.24万 - 项目类别:
Metabolic control of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的代谢控制
- 批准号:
10334766 - 财政年份:2021
- 资助金额:
$ 36.24万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10709559 - 财政年份:2020
- 资助金额:
$ 36.24万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10467982 - 财政年份:2020
- 资助金额:
$ 36.24万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10011124 - 财政年份:2020
- 资助金额:
$ 36.24万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10490344 - 财政年份:2020
- 资助金额:
$ 36.24万 - 项目类别:
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation
蛋白酶体和溶酶体降解之间相互作用的 NRF2-p62 轴
- 批准号:
9891075 - 财政年份:2017
- 资助金额:
$ 36.24万 - 项目类别:
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries
将脱细胞血管移植物转化为小直径动脉的新方法
- 批准号:
9317769 - 财政年份:2017
- 资助金额:
$ 36.24万 - 项目类别:
UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1 (UCH-L1) AND VASCULAR LESION FORMATION
泛素羧基末端水解酶 L1 (UCH-L1) 与血管病变形成
- 批准号:
8167799 - 财政年份:2010
- 资助金额:
$ 36.24万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 36.24万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 36.24万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 36.24万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 36.24万 - 项目类别:
Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
- 批准号:
23KK0126 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 36.24万 - 项目类别:
Training Grant